

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/37477Serial No.
09/880,417Applicant
Andrei V. Gudkov et al.Filing Date
June 13, 2001Group
1614

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Q	5,919,808	07/06/99	Petrie et al.	514	372	

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
Q	WO96/28454	19.09.96	PCT	C07D	513/04	Abstract	
Q	WO98/17267	30.04.98	PCT	A61K	31/165		
Q	11029475	02.02.99	Japan	A61K	31/425	Abstract	
Q	7291976	07.11.95	Japan	C07D	513/04	Abstract	
Q	11106340	20.04.99	Japan	A61K	31/425	Abstract	
Q	0 430 334	05.06.91	EPO	C07D	277/40		

EXAMINER

DATE CONSIDERED

9/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

TECH CENTER 1600/2800

OCT 17 2001

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27611/37477Serial No.
09/880,4Applicant
Andrei V. Gudkov et al.Filing Date
June 13, 2001Group
1614

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



TECH CENTER 600/2000

OCT 17 2001

RECEIVED

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

2	Komarova et al., "Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53," <i>Oncogene</i> , 17, pp. 1089-1096 (1998).
2	Andreani et al., "Thienylimidazo[2,1-b]thiazoles as inhibitors of mitochondrial NADH dehydrogenase," <i>Journal of Medicinal Chemistry</i> , Vol. 38, pp. 1090-1097 (1995).
2	Balse et al., "Condensed tetrahydrobenzothiazoles: Part III--synthesis fo 2-aryl-5,6,7,8-tetrahydroimidazo[2,1-b]benzothiazoles & 1,2,3,4-tetrahydrobenzimidazo[2,1-b]benzothiazoles & their 4/5 carbethoxy derivatives," <i>Indian Journal of Chemistry</i> , Vol. 19B, pp. 263-265 (1980).
2	Singh et al., "Heterocyclic systems containing bridgehead nitrogen atom: Part XXV--Syntheses of imidazo[2,1-b]benzothiazoles & quinoxalino[2,3:4',5']-imidazo[2',1'-b]benzothiazoles," <i>Indian J. Chem.</i> , Vol. 14B, pp. 997-998 (1976).
2	Naito et al., "Syntehsis of 2-phenylimidazo[2,1-b]benzothiazole derivatives as modulators of multidrug resistance for tumor cells," <i>J. Heterocyclic Chem.</i> , 34, pp. 1763-1767 (1997).
2	Kochergin et al., "Action of α -halo ketones on 2-mercaptoimidazoles," <i>J. Gen. Chem. U.S.S.R.</i> , 26, pp. 483-489 (1980).
2	P.G. Komarov et al., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy, <i>Science</i> , 285, pp. 1733-1737 (1999).
2	K.K. Bhargava et al., Tetramisole analogues as inhibitors of alkaline phosphatase, an enzyme involved in the resistance of neoplastic cells to 6-thiopurines, <i>Journal of Medicinal Chemistry</i> , 20, No. 4, pp. 563-566 (1977).
2	C.L. Baird et al., Synthesis, characterization and antitumor activity of platinum triamine complexes containing imidazothiazole ligands, <i>Inorganica Chimica Acta</i> , 256, pp. 253-262 (1997).

EXAMINER

DATE CONSIDERED

9/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	A. Singh et al., Heterocyclic systems containing bridgehead nitrogen atom: Part XXV--syntheses of imidazo[2,1- β]benzothiazoles & quinoxalino[2,3:4'5']imidazo[2',1'- β]benzothiazoles, <i>Indian J. Chem.</i> , 14B, pp. 997-998 (1976).
	S. Tasaka et al., Synthesis of 2-phenylimidazo[2,1- β]benzothiazole derivatives as modulators of multidrug resistance for tumor cells, <i>J. Heterocyclic Chemistry</i> , 34, pp. 1763-1767 (1997).
	S.N. Sawhney et al., Synthesis & anti-inflammatory activity of some 6-alkyl- or aryl-imidazo[2,1- β]thiazole-3-acetic acids, <i>Indian J. Chem.</i> , 16B, pp. 523-524 (1978).
	E.A. Komarova et al., Could p53 be a target for therapeutic suppression?, <i>Seminars in Cancer Biology</i> , 8, No. 5, pp. 389-400 (1998).
	R.J.C. Steele et al., The p53 tumour suppressor gene, <i>British Journal of Surgery</i> , 85, pp. 1460-1467 (1998).
	E.A. Komarova et al., Transgenic mice with p53-responsive <i>lacZ</i> :p53 activity varies dramatically during normal development and determines radiation and drug sensitivity <i>in vivo</i> , <i>The EMBO Journal</i> , 16, No. 6, pp. 1391-1400 (1997).
	Singh et al., <i>Indian J. Chem.</i> , Sect. B, 14B(12), 997-8 (1976).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.